Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Clinical Trials of Imported Drugs Unapproved in Japan to Be Stimulated
September 23, 2002
- BULLETIN
September 23, 2002
- Package Inserts Revised for Coadministration of Ribavirin, IFN
September 23, 2002
- WORLD NEWS IN BRIEF
September 23, 2002
- White Paper Focuses on Different Economic Conditions between Generations
September 23, 2002
- Ortho Clinical Diagnostics: HCV Antigen Test Kits
September 23, 2002
- NEW PRODUCTS
September 23, 2002
- Gastric Cancer Discovered in 0.29% of Individuals by Endoscopy
September 23, 2002
- Specialization in Niche Market Recommended for Japanese Companies: Dr Bouee
September 23, 2002
- Toshiba: New Biochemical Analyzer ARCHITECT c8000
September 23, 2002
- WEBSITE NEWS
September 16, 2002
- NEW PRODUCTS
September 16, 2002
- Draft Report on Activities of SMO Prepared: Korosho Council
September 16, 2002
- Korosho Specifies Ordinances to Follow PAL Amendment
September 16, 2002
- No Abnormalities in Health Checks Decreasing: JHA Report
September 16, 2002
- LDP to Consider "Independent Insurance" or "Age-risk Adjusted Program" for Elderly
September 16, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 16, 2002
- Council to Draft Bio-technology Strategy Principles
September 16, 2002
- Terumo Agrees with Diacrin for Myocardial Regeneration Therapy
September 16, 2002
- Korosho Clarifies Its Stance Regarding "Special Regulatory Reform Zone"
September 16, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…